carbamatebear
molecul
play
import
role
modern
drug
discoveri
medicin
chemistri
organ
carbam
urethan
structur
element
mani
approv
therapeut
agent
structur
carbam
function
relat
amideest
hybrid
featur
gener
display
good
chemic
proteolyt
stabil
carbam
wide
util
peptid
bond
surrog
medicin
chemistri
mainli
due
chemic
stabil
capabl
permeat
cell
membran
anoth
uniqu
featur
carbam
abil
modul
inter
intramolecular
interact
target
enzym
receptor
carbam
function
impos
degre
conform
restrict
due
deloc
nonbond
electron
nitrogen
carboxyl
moieti
addit
carbam
function
particip
hydrogen
bond
carboxyl
group
backbon
nh
therefor
substitut
ntermini
carbam
offer
opportun
modul
biolog
properti
improv
stabil
pharmacokinet
properti
carbam
manipul
use
design
prodrug
mean
achiev
firstpass
system
hydrolyt
stabil
carbam
deriv
wide
repres
agricultur
chemic
pesticid
fungicid
herbicid
play
major
role
chemic
paint
industri
start
materi
intermedi
solvent
furthermor
organ
carbam
serv
import
role
optimum
protect
group
amin
amino
acid
organ
synthesi
peptid
chemistri
recent
year
carbam
deriv
receiv
much
attent
due
applic
drug
design
discoveri
howev
hardli
review
subject
literatur
present
perspect
plan
provid
overview
lead
role
organ
carbam
medicin
chemistri
particular
focu
therapeut
carbam
carbamatebas
prodrug
context
highlight
chemic
methodolog
adopt
synthesi
carbam
deriv
also
outlin
success
design
organ
carbam
includ
varieti
cyclic
etherderiv
carbam
suitabl
amid
bond
surrog
lead
wide
rang
novel
organ
carbam
potent
proteas
serin
proteas
cystein
proteas
inhibitor
inform
may
use
design
carbamatebas
molecul
drug
prodrug
peptidebas
molecul
import
start
point
drug
discoveri
especi
design
enzym
inhibitor
high
affin
specif
toward
biolog
function
peptidebas
molecul
also
serv
valuabl
research
tool
howev
poor
vivo
stabil
inadequ
pharmacokinet
properti
low
bioavail
gener
limit
broader
util
henc
varieti
peptid
mimic
develop
improv
druglik
charact
along
increas
potenc
target
specif
longer
durat
end
sever
class
peptidomimet
tailor
replac
nativ
amid
bond
unnatur
peptid
bond
surrog
function
confer
metabol
stabil
toward
aminopeptidas
enzym
involv
metabol
peptidelik
drug
carbam
emerg
role
medicin
chemistri
also
due
chemic
stabil
capabl
increas
permeabl
across
cellular
membran
attribut
organ
carbam
exploit
drug
design
result
carbam
motif
becom
choic
peptid
bond
surrog
use
carbam
wellknown
particularli
employ
carbam
variou
industri
agrochem
polym
industri
also
peptid
addit
among
variou
amineprotect
group
carbam
commonli
use
enhanc
chemic
stabil
toward
acid
base
one
import
featur
organ
carbam
repres
amid
reson
amid
reson
carbam
studi
detail
employ
experiment
theoret
method
estim
bond
rotat
amid
reson
carbam
shown
kcal
lower
amid
owe
steric
electron
perturb
due
addit
three
possibl
reson
structur
b
c
figur
contribut
stabil
carbam
moieti
carbam
motif
character
pseudo
doubl
bond
impli
potenti
deconjug
heteroatom
carbon
heteroatom
system
restrict
free
rotat
formal
singl
therefor
two
isom
syn
anti
may
coexist
carbam
figur
although
carbam
display
close
similar
amid
show
prefer
antiisom
anti
rotam
usual
favor
kcal
steric
electrostat
reason
respect
syn
mani
case
energi
differ
may
close
zero
result
carbam
found
approxim
mixtur
syn
anti
isom
case
number
bocprotect
amino
acid
deriv
issu
key
import
sinc
balanc
rotam
equilibria
low
activ
energi
render
carbam
optim
conform
switch
molecular
influenc
r
substitu
freeenergi
differ
two
conform
investig
beyond
steric
effect
electroneg
must
consid
sinc
may
affect
conform
mani
way
includ
chang
dipol
moment
bond
anti
conform
would
expect
five
six
sevenmemb
cyclic
carbam
calcul
dipol
moment
carbam
group
support
solvent
concentr
salt
ph
strongli
influenc
free
energi
differ
syn
anti
isom
carbam
well
intra
intermolecular
hydrogen
bond
may
also
perturb
isom
equilibrium
repres
exampl
hydrogen
bond
concentr
depend
provid
gottlieb
nudelman
author
took
consider
nbocamino
acid
correspond
methyl
ester
unusu
abund
synrotam
nbocamino
acid
detect
nbocamino
acid
ester
give
expect
spectra
consist
previou
report
singl
speci
observ
room
temperatur
concentrationdepend
nmr
spectra
indic
proport
synrotam
increas
concentr
support
exist
aggreg
sinc
decreas
temperatur
anoth
method
stabil
oligomer
nmr
experi
also
perform
differ
temperatur
expect
temperatur
increas
favor
rotam
switch
syn
anti
overal
collect
data
strongli
support
concept
syn
rotam
ncarbamoyl
amino
acid
form
intermolecularli
hbond
speci
oh
carboxyl
acid
must
involv
process
correspond
ester
behav
similarli
explain
phenomenon
format
dimer
suggest
figur
support
hypothesi
provid
ad
increas
amount
acet
acid
solut
carbamoyl
amino
acid
ester
expect
syn
rotam
appear
concentr
increas
function
amount
acid
ad
contrast
addit
acet
acid
solut
correspond
carbamoyl
amino
acid
affect
antisyn
ratio
context
moraczewski
cowork
design
effect
hydrogenbond
system
select
perturb
synanti
rotam
equilibrium
target
carbam
author
examin
abil
acet
acid
octylamido
pyridin
perturb
synanti
ratio
carbam
figur
solut
acet
acid
moder
stabil
doubl
hydrogen
bond
syn
rotam
phenyl
carbam
figur
relev
effect
synanti
ratio
carbam
figur
second
case
carboxyl
acid
favor
donat
hydrogen
bond
basic
pyridyl
nitrogen
form
complex
shown
figur
contrari
case
triad
strongli
stabil
syn
rotam
figur
anti
rotam
figur
effect
synanti
ratio
presum
steric
deterr
format
hydrogenbond
complex
figur
carbam
moieti
play
noteworthi
role
medicin
chemistri
found
drug
also
presenc
number
rate
level
hydrolysi
key
issu
durat
intens
pharmacolog
activ
fast
hydrolysi
carbamatebear
drug
may
result
weak
shorten
activ
contrari
carbamatebas
prodrug
must
undergo
extens
hydrolysi
suitabl
rate
releas
activ
drug
obtain
expect
activ
profil
vacondio
et
al
recent
propos
interest
studi
compil
larg
number
reliabl
literatur
data
metabol
hydrolysi
therapeut
author
abl
exploit
collect
data
gain
qualit
relationship
molecular
structur
labil
metabol
hydrolysi
trend
extrapol
accord
metabol
labil
carbam
decreas
follow
seri
aryloconhalkyl
alkyloconhalkyl
alkylocon
alkyl
alkylocon
endocycl
arylocon
alkyl
arylocon
endocycl
alkyloconharyl
alkyloconhacyl
cyclic
therefor
carbam
deriv
ammonia
aliphat
amin
suffici
longliv
exampl
repres
cefoxitin
secondgener
cephalosporin
antibiot
figur
cyclic
five
sixmemb
carbam
quit
stabl
usual
undergo
metabol
ring
open
antibacteri
agent
linezolid
repres
exampl
class
figur
drug
carbam
hydrolysi
necessarili
halflifedetermin
metabol
reaction
contrari
fatti
acid
amid
hydrolas
faah
inhibitor
show
signific
hydrolysi
buffer
physiolog
ph
h
figur
repres
therapeut
carbam
drug
prodrug
discuss
section
respect
year
varieti
carabam
prepar
util
hofmann
rearrang
curtiu
rearrang
acyl
reduct
carbonyl
carbonyl
reaction
alcohol
carbon
dioxid
hofmann
rearrang
method
scheme
wellrecogn
use
method
convert
primari
carboxamid
amin
carbam
character
reduct
one
carbon
much
effort
devot
develop
modifi
reagent
optim
hofmann
rearrang
sinc
classic
method
transform
involv
use
alkalin
solut
bromin
unsatisfactori
varieti
oxid
base
propos
modifi
agent
eg
iodin
iii
reagent
phi
oac
lead
benzyltrimethylammonium
modifi
method
howev
requir
equiv
excess
amount
oxid
reagent
conveni
curtiu
rearrang
method
ii
scheme
thermal
decomposit
acyl
azid
isocyan
intermedi
method
wide
employ
transform
carboxyl
acid
carbam
urea
acyl
azid
usual
prepar
carboxyl
acid
deriv
acyl
mix
subsequ
isocyan
intermedi
trap
varieti
nucleophil
provid
carbam
deriv
acid
chlorid
method
suitabl
acidsensit
function
onepot
transform
carboxyl
acid
carbam
avoid
isol
unstabl
acyl
azid
howev
protocol
involv
use
diphenylphosphoryl
azid
dppa
onepot
curtiu
reaction
also
character
issu
relat
toxic
high
boil
point
dppa
creat
difficulti
workup
gener
method
carbam
prepar
involv
use
highli
toxic
phosgen
signific
effort
made
find
altern
phosgen
process
attract
substitut
phosgen
carbon
dioxid
classic
renew
resourc
method
iii
scheme
addit
use
also
attract
due
environment
benign
natur
nontox
noncorros
nonflamm
carbon
dioxid
wellknown
react
rapidli
amin
form
carbam
acid
ammonium
salt
major
approach
context
reli
creation
carbam
anion
via
reaction
carbon
dioxid
amin
follow
reaction
electrophil
nevertheless
sinc
nucleophil
carbam
anion
lower
amin
form
equilibrium
salt
format
subsequ
reaction
carbam
salt
alkyl
halid
select
provid
format
carbam
isocyan
method
iv
scheme
fundament
import
polyurethan
industri
synthet
limit
toxic
issu
howev
associ
use
phosgen
common
rout
obtain
readili
avail
alkyl
chloroform
frequent
use
reagent
prepar
carbam
method
v
scheme
howev
reagent
display
major
drawback
larg
excess
base
long
reaction
time
requir
order
gain
accept
reaction
effici
moreov
excess
reagent
suitabl
synthesi
molecul
bear
multipl
function
chemoselect
number
organ
carbon
develop
lowcost
benign
altern
phosgenebas
rout
synthesi
organ
carbam
context
sever
new
alkoxycarbonyl
agent
base
mix
carbon
develop
figur
method
often
use
synthesi
carbam
drug
mix
carbon
pnitrophenyl
moieti
frequent
use
prepar
larg
rang
pnitrophenyl
chloroform
pnpcocl
treat
suitabl
alcohol
presenc
base
furnish
correspond
activ
carbon
shown
use
effect
alkoxycarbonyl
reagent
suitabl
amin
scheme
exampl
carbam
deriv
shown
tabl
sever
alkoxycarbonyl
reagent
amino
group
heterocycl
group
nhydroxyimid
report
moreov
util
versatil
carbon
oxal
contain
electronwithdraw
group
nhydroxyimid
benzotriazol
deriv
reagent
variou
tranform
takeda
et
al
report
trifluoromethyl
benzotriazolyl
carbon
easili
deriv
trifluoromethyl
benzotriazolyl
carbon
btbc
show
high
acyl
reactiv
toward
alcohol
well
amino
btbc
prepar
trichloromethyl
chloroform
purifi
wash
dri
ether
moreov
store
sever
month
freezer
btbc
allow
react
primari
alcohol
acetonitril
room
temperatur
give
stabl
activ
carbon
carbon
treat
amin
presenc
dmap
provid
correspond
carbam
scheme
tabl
connect
research
work
aim
synthes
biolog
activ
polyfunct
molecul
probe
enzym
activ
site
requir
gener
synthet
reliabl
method
synthesi
variou
carbam
deriv
describ
util
di
carbon
dpc
effici
highyield
conveni
alkoxycarbonyl
reagent
amin
overcom
mani
limit
exist
dpc
readili
prepar
commerci
avail
triphosgen
presenc
triethylamin
subsequ
react
suitabl
primari
secondari
alcohol
eg
menthol
provid
mix
carbon
alkoxycarbonyl
primari
secondari
amin
mix
carbon
carri
presenc
triethylamin
furnish
correspond
carbam
good
yield
scheme
method
tabl
potassium
hydrid
use
place
triethylamin
prepar
mix
carbon
contain
tertiari
alcohol
scheme
tabl
subsequ
investig
scope
n
carbon
dsc
promot
alkoxycarbonyl
amin
host
alcohol
mild
rich
cowork
highlight
conveni
succinimidylbas
mix
carbon
highyield
introduct
trimethylsilyl
ethoxycarbonyl
teoc
protect
group
amino
acid
without
oligopeptid
byproduct
dsc
found
highli
effect
alkoxycarbonyl
reagent
varieti
primari
steric
hinder
secondari
alcohol
dsc
commerci
avail
conveni
prepar
nhydroxysuccinimid
follow
procedur
trace
synthesi
readi
avail
dsc
stabil
mix
carbon
mild
reaction
procedur
render
method
reliabl
rout
organ
carbam
scheme
tabl
sinc
azid
extens
employ
incipi
amin
context
amino
sugar
amino
acid
synthes
convers
correspond
carbam
deriv
could
provid
novel
effect
rout
medicin
chemistri
applic
context
facil
synthet
protocol
transform
variou
azid
correspond
function
urethan
high
yield
gener
mix
carbon
various
protect
alcohol
prepar
reaction
excess
dsc
dpc
describ
previous
exposur
mix
carbon
catalyt
hydrogen
condit
azid
presenc
palladium
charcoal
tetrahydrofuran
furnish
correspond
carbam
interestingli
use
triethylamin
promot
notabl
effect
yield
rate
alkoxycarbonyl
process
scheme
tabl
recent
yoon
cowork
exploit
one
electrophil
transfer
particular
author
investig
carbonyl
potenc
phenyl
carboxyl
amin
prepar
phenylcarbam
scheme
tabl
compound
stabl
air
organ
solvent
high
temperatur
prepar
easili
cheap
commerci
avail
one
presenc
phenylchloroform
triethylamin
scheme
applic
carbon
dioxid
organ
synthesi
recent
attract
much
interest
approach
reli
gener
carbam
anion
via
reaction
carbon
dioxid
amin
follow
reaction
electrophil
usual
alkyl
context
mild
effici
prepar
alkyl
carbam
solid
support
describ
jung
et
amin
anilin
coupl
merrifield
resin
linker
presenc
cesium
carbon
tetrabutylammonium
iodid
tbai
carbon
dioxid
suppli
bubbl
reaction
suspens
n
ndimethylformamid
dmf
solvent
choic
scheme
reaction
condit
conveni
purif
reaction
undergo
complet
convers
method
conveni
gener
larg
combinatori
librari
rapid
screen
bioactiv
molecul
chiral
substrat
suscept
racem
surviv
condit
tabl
later
author
report
onepot
synthesi
nalkyl
carbam
start
primari
amin
scheme
carbam
gener
via
threecompon
coupl
primari
amin
alkyl
halid
presenc
cesium
carbon
tbai
anhydr
dmf
scheme
tabl
direct
nalkyl
intermedi
carbam
presenc
addit
cesium
carbon
use
differ
alkyl
halid
gave
rise
desir
nalkyl
carbam
b
scheme
isol
intermedi
prove
unnecessari
offer
shorten
synthet
interest
note
tbai
help
minim
overalkyl
produc
carbam
presum
enhanc
rate
incorpor
andor
stabil
incipi
carbam
anion
conjug
tetrabutylammonium
sakakura
cowork
report
urethan
synthesi
reaction
dens
carbon
dioxid
amin
alcohol
procedur
phosgenefre
also
complet
halogenfre
scheme
dialkyl
carbon
synthesi
alcohol
catalyz
metal
complex
dialkyl
oxo
tin
dialkyl
dichloro
tin
howev
alcohol
convers
poor
similarli
direct
reaction
amin
alcohol
carbon
dioxid
presenc
dialkyltin
compound
produc
urethan
poor
yield
low
convers
observ
attribut
author
thermodynam
limit
catalyst
deactiv
coproduc
water
order
overcom
issu
new
reaction
system
util
acet
chemic
dehydr
agent
subsequ
alcohol
regener
scheme
develop
order
obtain
urethan
good
yield
densephas
high
pressur
necessari
lower
major
side
reaction
name
imin
format
aceton
alkyl
amin
alcohol
howev
develop
less
toxic
activ
catalyst
base
metal
tin
requir
later
author
report
novel
nickelbas
catalyt
system
dehydr
urethan
format
carbon
dioxid
amin
alcohol
scheme
interestingli
ad
nitrogenbas
bident
ligand
effici
improv
catalyt
activ
ni
oac
catalyst
scheme
tabl
bipyridin
phenanthrolin
strong
coordin
abil
low
steric
hindranc
high
electron
densiti
better
choic
obtain
urethan
high
yield
import
note
niphenanthrolin
system
activ
less
toxic
dialkyl
oxo
tin
reaction
condit
also
noteworthi
catalyt
activ
ni
oac
system
highli
depend
ligandmet
ratio
tabl
peterson
cowork
propos
method
rapid
sar
develop
compound
bear
urea
carbam
function
scheme
carbam
format
amin
principl
could
proceed
carbam
reaction
subsequ
reaction
alcohol
may
provid
carbam
product
preced
intramolecular
reaction
variant
produc
cyclic
desir
intermolecular
coupl
fruit
propos
reaction
condit
carbam
acid
produc
secondari
amin
howev
react
alcohol
mitsunobu
condit
dibenzyl
azodicarboxyl
dbad
tributylphosphin
dbucatalyz
reaction
gaseou
carbon
dioxid
provid
correspond
carbam
scheme
tabl
reaction
proceed
isocyan
intermedi
rather
displac
activ
alcohol
hypothesi
support
observ
invers
stereochemistri
upon
convers
chiral
secondari
alcohol
correspond
carbam
tabl
recent
jiao
cowork
report
practic
effici
assembl
organ
azid
carbon
monoxid
alcohol
direct
synthesi
carbam
via
isocyan
format
applic
situ
scheme
mild
neutral
reaction
condit
gener
harmless
byproduct
render
protocol
use
particularli
synthesi
bioactiv
compound
moreov
employ
co
atmospher
pressur
use
small
amount
catalyst
mol
absenc
ligand
repres
real
altern
customari
carbam
synthet
method
tabl
synthesi
carbam
gener
carbamoyl
chlorid
conveni
requir
toxic
phosgen
also
carbamoyl
chlorid
highli
reactiv
prone
hydrolysi
unstabl
suitabl
longterm
storag
problem
batey
cowork
identifi
use
carbamoylimidazolium
salt
conveni
n
carbamoyl
transfer
reagent
show
increas
reactiv
carbamoylimidazol
result
imidazolium
effect
scheme
salt
readili
prepar
sequenti
treatment
secondari
amin
n
cdi
iodomethan
scheme
author
envisag
carbamoylimidazolium
salt
rel
unreact
alcohol
would
react
nucleophl
alkoxid
produc
correspond
carbam
tabl
case
phenol
tertiari
amin
appropri
base
situ
gener
reactiv
phenoxid
lower
acid
aliphat
alcohol
presum
prevent
format
alkoxid
anion
would
serv
reactiv
nucleophil
less
acid
alcohol
react
carbamoylimidazolium
convers
nucleophil
sodium
alkoxid
scheme
use
solidsupport
reagent
becom
ubiquit
due
enhanc
reactiv
select
milder
reaction
condit
conveni
workup
decreas
solvent
wast
modifi
hofmann
rearrang
propos
gogoi
et
al
oper
simpl
inexpens
applic
varieti
aliphat
aromat
amid
synthesi
methyl
carbam
scheme
repres
use
interest
solidsupport
strong
base
replac
organ
base
varieti
sodium
hypochlorit
inexpens
conveni
safe
altern
current
employ
prompt
author
investig
along
naocl
effici
reagent
system
hofmann
rearrang
basic
stem
format
koh
initi
prepar
solidsupport
materi
reaction
kf
alumina
support
highli
basic
reaction
condit
hypochlorit
ion
predomin
form
chlorin
react
amid
form
nchloroamid
later
undergo
rearrang
isocyan
presenc
methanol
isocyan
rapidli
convert
correspond
methyl
carbam
tabl
modif
curtiu
rearrang
also
explor
lebel
cowork
report
use
protocol
prepar
tertbutyl
carbam
correspond
carboxyl
reaction
ditertbutyl
dicarbon
sodium
azid
led
format
correspond
acyl
azid
undergo
curtiu
rearrang
presenc
tetrabutylammonium
bromid
zinc
ii
triflat
provid
carbam
trap
isocyan
intermedi
scheme
tabl
author
extend
methodolog
direct
synthesi
carbam
aromat
amin
use
aromat
carboxyl
acid
scheme
tabl
particular
reaction
chloroform
ditertbutyl
dicarbon
sodium
azid
aromat
carboxyl
acid
produc
correspond
acyl
azid
presum
format
azidoform
contrast
observ
aliphat
carboxyl
acid
use
similar
reaction
condit
aromat
carboxyl
acid
led
mainli
format
correspond
tertbutyl
ester
like
via
displac
azid
leav
group
tertbutoxid
may
ascrib
higher
stabil
aromat
acyl
azid
respect
aliphat
counterpart
therefor
substrat
curtiu
rearrang
promot
higher
temperatur
vs
mention
alkyl
chloroform
frequent
use
reagent
prepar
carbam
although
need
excess
amount
limit
use
promis
method
prepar
carbam
involv
use
catalyt
late
indiummedi
reaction
gain
signific
consider
due
high
reactiv
uniqu
properti
indium
reagent
among
nontox
inert
toward
air
moreov
pretreat
requir
activ
indium
metal
context
jang
cowork
develop
simpl
effici
select
method
synthes
carbam
amin
employ
catalyt
amount
indium
equimolar
amount
alkyl
chloroform
scheme
method
show
gener
wide
varieti
steric
divers
amin
alcohol
also
applic
select
protect
amino
group
mild
condit
tabl
arndtsen
et
al
propos
anoth
applic
indiumbas
reagent
gener
nprotect
amin
singl
step
scheme
tabl
sinc
organoindium
reagent
readili
transfer
organ
group
imin
carbon
onethird
equival
requir
byproduct
repres
indium
trichlorid
tetraorganoindium
reagent
also
employ
similar
fashion
transfer
four
organ
group
therefor
onefourth
equival
indium
necessari
reaction
imin
copper
chlorid
found
effici
catalyst
sodeoka
colleagu
report
use
reagent
use
intermedi
prepar
carbam
scheme
achiev
rapid
clean
reaction
featur
leav
group
key
role
ideal
leav
group
highli
electronwithdraw
element
order
increas
electrophil
carbonyl
carbon
nucleophil
low
avoid
side
reaction
also
easili
separ
reaction
product
nt
although
show
nucleophil
could
easili
remov
reaction
due
insolubl
dichloromethan
chloroform
ntbase
reagent
seri
benefit
high
stabil
sinc
store
long
period
without
decomposit
reaction
nt
reagent
primari
secondari
amin
proceed
quickli
give
correspond
carbam
yield
scheme
tabl
contrast
aliphat
amin
aromat
amin
less
reactiv
howev
addit
triethylamin
found
effect
promot
reaction
scheme
tabl
reduct
carbonyl
aromat
nitro
compound
correspond
carbam
remain
subject
great
interest
mechanist
applic
standpoint
scheme
section
briefli
mention
methodolog
involv
use
alcohol
although
procedur
employ
chloroform
also
recent
cheng
collabor
report
use
ru
co
co
complex
catalysi
reaction
highlight
key
effect
alcohol
select
carbam
tabl
result
clearli
indic
low
select
carbam
close
relat
abil
alcohol
reduc
nitroaren
amino
deriv
therefor
employ
alcohol
reduc
nitroaren
greatli
increas
select
carbam
later
binuclear
rhodium
complex
employ
effect
catalyst
reduct
carbonyl
nitrobenzen
carbam
ester
tabl
palladiumbas
catalyst
also
explor
tabl
carbam
synthesi
via
transfunction
substitut
urea
carbon
presenc
dinbutyltin
oxid
dbto
catalyst
report
chaudhari
colleagu
scheme
tabl
carbon
reactiv
pattern
seem
driven
leav
group
abil
alkoxid
phenoxid
form
carbam
observ
aminolysi
carbon
shown
basic
react
urea
play
vital
role
catalyt
activ
reaction
inde
aliphat
urea
show
higher
reactiv
compar
aromat
urea
due
higher
basic
basic
dbto
suppos
work
nucleophil
attack
carbonyl
carbon
carbon
thu
gener
catalyt
activ
speci
dibutyl
alkoxi
carbonato
tin
shown
speci
interact
substitut
urea
elimin
one
molecul
carbam
form
dibutyl
alkoxi
carbamato
tin
b
reaction
speci
b
carbon
result
format
one
molecul
carbam
regener
activ
speci
scheme
use
dialkyl
carbon
environment
friendli
nontox
phosgen
substitut
alkoxycarbonyl
reaction
also
exploit
porco
et
al
scheme
particularli
author
examin
scope
zr
iv
catalyz
exchang
process
prepar
carbam
dialkyl
carbon
employ
hyp
catalyt
addit
tabl
recent
padiya
cowork
report
use
method
prepar
carbam
aqueou
media
scheme
interestingli
found
cdi
although
unstabl
water
rapidli
react
aqueou
media
amin
give
good
yield
correspond
nsubstitut
carbonylimidazolid
carbonylimidazolid
deriv
primari
amin
react
situ
nucleophil
phenol
provid
correspond
carbam
product
precipit
reaction
mixtur
obtain
high
puriti
filtrat
make
method
simpl
scalabl
tabl
cdi
also
found
mediat
lossen
rearrang
occur
transform
activ
hydroxam
acid
correspond
isocyan
scheme
propos
methodolog
experiment
effici
mild
character
imidazol
stoichiometr
byproduct
method
green
unconvent
altern
curtiu
hofmann
rearrang
tabl
anoth
method
base
lossen
rearrang
recent
methodolog
envisag
reaction
hydroxam
acid
alcohol
promot
cyanur
chlorid
tct
presenc
excess
nmethyl
morpholin
nmm
scheme
tabl
rivastigmin
figur
tartrat
exelon
novarti
pharma
carbam
deriv
revers
inhibit
metabol
acetylcholinesteras
ach
butyrylcholinesteras
buch
preferenti
central
nervou
system
cn
use
treatment
mildtomoder
alzheim
diseas
ad
dementia
dementia
due
parkinson
drug
administ
oral
via
transderm
patch
transderm
patch
reduc
side
effect
nausea
vomit
rivastigmin
undergo
extens
metabol
chemedi
hydrolysi
decarbamyl
metabolit
without
involv
major
cytochrom
isozym
metabolit
may
undergo
ndemethyl
well
conjug
pharmacokinet
halflif
rivastigmin
ad
patient
around
h
given
oral
rivastigmin
wellabsorb
bioavail
administ
mg
muraglitazar
contain
carbam
function
potent
novel
nonthiazolidindion
peroxisom
proliferatoractiv
receptor
dual
agonist
demonstr
highli
efficaci
glucos
lipid
lower
activ
vivo
along
excel
adm
doubleblind
random
clinic
trial
muraglitazar
result
statist
signific
improv
plasma
triglycerid
hdl
cholesterol
apob
nonhdl
cholesterol
concentr
week
muraglitazar
reduc
triglycerid
concentr
larger
extent
pioglitazon
regardless
baselin
triglycerid
level
muraglitazar
pioglitazon
treatment
associ
slight
increas
ldl
cholesterol
howev
muraglitazar
develop
discontinu
due
major
advers
cardiovascular
side
roxifiban
carbam
deriv
methyl
ester
prodrug
potent
nonpeptid
antagonist
glycoprotein
iibiiia
free
acid
result
roxifiban
hydrolysi
block
bind
fibrinogen
receptor
therebi
inhibit
platelet
aggreg
provid
mechan
antithrombot
therapi
howev
clinic
develop
roxifiban
discontinu
octob
entinostat
contain
pyridylmethyl
carbam
undergo
clinic
trial
treatment
variou
cancer
entinostat
preferenti
inhibit
nm
report
inhibitori
activ
toward
drug
induc
cyclindepend
kinas
inhibitor
therebi
slow
cell
growth
differenti
tumor
develop
vivo
recent
studi
suggest
may
particularli
use
antineoplast
agent
combin
drug
like
albendazol
albenza
teva
pharmaceut
broadspectrum
anthelmint
carbam
drug
undergo
rapid
hepat
oxid
liver
microsom
enzym
produc
activ
metabolit
albendazol
sulfoxid
oxid
inact
metabolit
albendazol
sulfon
mebendazol
methyl
carbam
deriv
show
broadspectrum
anthelmint
properti
demonstr
efficaci
oral
treatment
ascariasi
uncinariasi
oxyuriasi
trichuriasi
like
benzimidazol
anthelmint
mebendazol
primari
mechan
action
consist
tubulin
mebendazol
discontinu
flupirtin
retigabin
ethyl
carbam
deriv
flupirtin
central
act
nonopioid
identifi
within
antiepilept
drug
discoveri
program
us
nation
institut
health
dose
use
small
clinic
trial
exceed
establish
analges
basi
data
subsequ
structur
optim
result
retigabin
anticonvuls
properti
appear
mediat
open
activ
neuron
voltageg
potassium
channel
flupirtin
show
nmethyldaspart
nmda
receptor
antagonist
properti
felbam
felbatol
meda
pharmaceut
alkyl
carbam
deriv
antiepilept
drug
mechan
action
felbam
involv
dual
mechan
involv
inhibit
nmethyldaspart
nmda
receptor
respons
posit
modul
butyr
acid
subtyp
gabaa
receptor
thu
decreas
neuron
felbam
rapidli
absorb
tmax
h
oral
bioavail
felbam
undergo
moder
metabol
via
isoenzym
amen
inhibit
induct
clinic
use
felbam
declin
recent
year
due
seriou
advers
side
effect
efavirenz
sustiva
stocrin
bristolmy
squibb
cyclic
carbam
deriv
nonnucleosid
revers
transcriptas
inhibitor
nnrti
drug
use
part
highli
activ
antiretrovir
therapi
haart
howev
use
associ
variabl
treatment
respons
advers
effect
part
larg
differ
main
enzym
catalyz
major
clearanc
mechan
efavirenz
zafirlukast
accol
astrazeneca
cyclopentyl
naryl
carbam
deriv
select
competit
receptor
antagonist
cysteinyl
leukotrien
indic
prophylaxi
treatment
mildtomoder
persist
chronic
nh
bioisoster
analogu
zafirlukast
found
potent
carbam
moieti
present
zafirlukast
provid
excel
vitro
vivo
profil
high
oral
zafirlukast
undergo
hepat
metabol
hydroxyl
cytochrom
major
biotransform
pathway
metabolit
zafirlukast
significantli
contribut
overal
mitomycin
c
mmc
mutamycin
complex
carbam
deriv
antitumor
antibiot
identifi
ferment
cultur
gramneg
bacteria
streptomyc
mmc
sitespecif
nondistort
dna
crosslink
howev
recent
report
suggest
dna
may
primari
target
drug
particular
interact
mmc
rrna
subsequ
inhibit
protein
translat
mmc
customarili
use
chemotherapeut
agent
treatment
sever
type
cancer
bladder
colon
breast
ritonavir
norvir
abbvi
inc
structur
possess
thiazolyl
methyl
carbam
function
peptidomimet
inhibitor
proteas
approv
fda
march
firstgener
proteas
inhibitor
develop
abbott
laboratori
discoveri
ritonavir
base
studi
diamin
subunit
ritonavir
show
bioavail
plasma
halflif
h
ritonavir
high
molecular
weight
howev
show
excel
pharmacokinet
properti
possibl
due
increas
stabil
thiazol
group
oxid
metabol
also
due
effect
cytochrom
oxid
enzym
ritonavir
type
ii
heme
ligand
fit
activ
site
caviti
irrevers
bind
heme
iron
via
thiazol
inhibit
ritonavir
increas
plasma
concentr
antihiv
drug
oxid
therebi
improv
clinic
efficaci
amprenavir
ageneras
glaxosmithklin
vertex
tetrahydrofuranyl
carbam
deriv
approv
fda
april
amprenavir
identifi
potent
oral
bioavail
proteas
inhibitor
low
molecular
weight
mean
market
twiceaday
dose
format
amprenavir
structur
bear
stereochem
defin
tetrahydrofuranylcarbam
engag
weak
backbon
interact
vitro
vivo
studi
shown
amprenavir
primarili
metabol
two
major
metabolit
result
oxid
tetrahydrofuran
anilin
atazanavir
atv
reyataz
atv
sulfat
bristolmy
squibb
methyl
carbam
deriv
hydroxyethylen
hydrazidebas
secondgener
hivproteas
inhibitor
develop
late
approv
fda
june
atv
contain
two
methylcarbam
function
show
potent
enzym
inhibitori
activ
ki
nm
antivir
hivmninfect
cell
atv
display
excel
bioavail
favor
pharmacolog
profil
atv
rais
possibl
oncedaili
darunavir
drv
possess
structurebas
design
bistetrahydrofuranyl
bisthf
carbam
function
new
gener
proteas
inhibitor
improv
bioavail
potenc
drug
properti
drv
also
maintain
high
potenc
multidrugresist
strain
design
drv
origin
backbon
bind
concept
envisag
effect
proteas
inhibitor
maxim
rich
network
hydrogenbond
interact
backbon
atom
throughout
activ
site
bisthf
moieti
present
drv
design
base
xray
structur
proteas
complex
bisthf
carbam
moieti
drv
found
essenti
enzym
affin
see
figur
detail
drv
demonstr
except
potenc
wildtyp
hiv
isol
wide
rang
resist
drv
receiv
fda
approv
treatment
hivaid
patient
harbor
multidrugresist
variant
drv
receiv
full
approv
treatment
therapyna
adult
drv
metabol
isoenzym
howev
presenc
low
dose
ritonavir
drv
exhibit
good
pharmacokinet
properti
therapeut
relev
carbam
prodrug
design
substrat
specif
enzym
antibodydirect
enzym
prodrug
therapi
adept
genedirect
enzym
prodrug
therapi
gdept
new
strategi
target
tumor
carboxypeptidas
enzym
bacteri
origin
shown
catalyz
cleavag
amid
carbam
urea
linkag
glutam
acid
aromat
group
basi
specif
larg
number
prodrug
design
synthes
shown
figur
prodrug
activ
hydrolysi
carbam
bond
correspond
potent
diiodophenol
mustard
found
possess
best
profil
term
enzymat
kinet
cytotox
vivo
efficaci
select
clinic
develop
halflif
drug
approxim
min
enough
diffus
tumor
cell
local
releas
site
minim
peripher
irinotecan
design
deliv
camptothecin
predomin
topoisomeras
inhibitor
anticanc
therapi
irinotecan
hydrochlorid
salt
camptosar
pfizer
parenter
aqueou
solubl
carbam
prodrug
antineoplast
topoisomeras
inhibitor
potent
antitumor
activ
irinotecan
due
rapid
format
activ
metabolit
vivo
figur
molecul
dipiperidino
ioniz
promoieti
link
phenol
function
carbam
bond
thu
improv
overal
aqueou
bioconvers
back
occur
primarili
human
liver
microsom
carboxylesteras
ce
releas
ioniz
piperidinopiperidin
promoieti
activ
form
beyond
minim
rate
enzymat
hydrolysi
prodrug
sustain
drug
action
also
provid
decreas
rate
drug
metabol
case
bambuterol
bambec
astrazeneca
bisdimethyl
carbam
prodrug
terbutalin
use
bronchodil
treatment
asthma
phenol
moieti
terbutalin
subject
rapid
presystem
metabol
bambuterol
protect
function
also
avoid
firstpass
intestin
hepat
metabol
prodrug
inact
howev
oral
administr
slowli
convert
terbutalin
mainli
outsid
lung
seri
hydrolysi
oxid
reaction
maili
catalyz
plasma
cholinesteras
pche
figur
allow
oncedaili
bambuterol
treatment
respect
three
daili
terbutalin
n
ethylenediamin
spacer
use
evalu
cyclizationeliminationbas
prodrug
use
develop
prodrug
part
adept
activ
strategi
activ
specif
enzym
termin
amino
group
spacer
activ
initi
intramolecular
cycliz
reaction
elimin
parent
drug
parallel
releas
cycliz
spacer
one
applic
scherren
et
explor
particularli
interest
free
group
import
biolog
activ
gener
carbam
linkag
stabl
vivo
ester
carbon
sinc
proteolyt
activ
form
plasmin
locat
tumor
link
cytotox
drug
plasmin
substrat
may
result
tumorselect
deliveri
basi
rational
follow
plasmin
hydrolysi
spacer
expect
undergo
spontan
cycliz
yield
cyclic
urea
deriv
imidazolidinon
therebi
releas
paclitaxel
illustr
scheme
amin
group
one
common
function
group
mani
approv
drug
amin
drug
caus
physicochem
hurdl
potenti
limit
safeti
effect
deliveri
desir
site
action
therefor
varieti
prodrug
amin
design
overcom
formul
deliveri
barrier
carbam
function
util
mani
prodrug
strategi
design
amin
shortliv
carbam
also
use
prodrug
heteroaromat
amin
gabapentin
neurontin
pfizer
figur
structur
analogu
acid
gaba
market
anticonvuls
analges
agent
gabapentin
show
number
limit
includ
satur
absorpt
high
interpati
variabl
lack
dose
proportion
short
halflif
gabapentin
enacarbil
horiz
previous
known
carbam
prodrug
gabapentin
prodrug
benefit
monocarboxyl
transport
type
express
segment
colon
upper
gastrointestin
tract
prodrug
also
help
sodiumdepend
multivitamin
transport
smv
respons
absorpt
multipl
essenti
follow
absorpt
via
pathway
prodrug
rapidli
convert
gabapentin
nonspecif
esteras
mainli
enterocyt
lesser
extent
liver
convers
gabapentin
molecul
also
gener
carbon
dioxid
acetaldehyd
isobutyr
figur
oral
bioavail
improv
monkey
show
doseproport
gabapentin
exposur
xenoport
receiv
fda
approv
horiz
treatment
moderatetosever
restless
leg
syndrom
horiz
also
approv
manag
postherpet
neuralgia
phn
capecitabin
xeloda
roch
design
achiev
greater
select
activ
form
oral
administ
carbam
prodrug
belong
fluoropyrimidin
carbam
class
requir
cascad
three
enzym
bioconvers
activ
shown
figur
enzymat
bioconvers
start
liver
human
carboxylesteras
cleav
carbam
ester
intact
capecitabin
absorb
intestin
bioconvers
liver
releas
parent
drug
extent
bioconvers
proce
tumor
thu
avoid
system
toxic
particular
remain
transform
catalyz
cytidin
deaminas
thymidin
phosphorylas
latter
enzym
highli
enrich
tumor
thu
provid
select
releas
cancer
absorpt
capecitabin
evid
sinc
oral
administ
dose
recov
urin
tmax
reach
approxim
capecitabin
current
approv
first
line
therapi
colorect
breast
cancer
also
approv
use
combin
anticanc
alkoxycarbonyl
deriv
serv
use
prodrug
benzamidin
exampl
methoxycarbonyl
methyl
ester
lefradafiban
boehring
ingelheim
germani
effect
convert
activ
platelet
aggreg
inhibitor
fradafiban
bibu
oral
administr
reveal
monitor
plasma
concentr
ex
vivo
platelet
aggreg
studi
lefradafiban
oral
activ
prodrug
fradafiban
glycoprotein
iibiiia
receptor
esteras
enzym
involv
convers
lefradafiban
fradafiban
vivo
figur
year
develop
seri
novel
proteas
inhibitor
incorpor
cyclic
etherderiv
carbam
design
base
xray
structur
proteas
endeavor
specif
develop
stereochem
defin
cyclic
ether
templat
cyclic
ether
oxygen
could
effect
replac
peptid
carbonyl
oxygen
advantag
replac
reduc
peptid
featur
improv
metabol
stabil
compound
cyclic
ligand
incorpor
carbam
deriv
evolut
carbam
structur
templat
shown
figur
basi
xray
crystal
structur
saquinavir
bound
proteas
first
investig
r
tetrahydrofuranylglycin
r
thf
ring
oxygen
would
interact
nh
similar
asparagin
side
chain
carbonyl
oxygen
saquinavir
compound
effort
reduc
molecular
weight
quinolin
remov
amid
bond
replac
carbam
provid
inhibitor
signific
reduct
molecular
weight
da
da
xray
crystal
structur
proteas
reveal
ring
oxygen
tetrahydrofuran
thf
within
proxim
form
hydrogen
bond
nh
bond
subsit
import
carbam
moieti
evid
carbam
nh
form
hydrogen
bond
backbon
carbonyl
carbam
carbonyl
function
make
tightli
bound
watermedi
hydrogen
bond
backbon
nh
flap
activ
site
investig
thf
inhibitor
contain
hydroxyethylen
isoster
led
seri
except
potent
shown
tabl
thfcontain
carbam
driv
compound
provid
potent
inhibitor
antivir
assay
potenc
enhanc
effect
thf
carbam
subsequ
demonstr
inhibitor
contain
r
hydroxyethyl
sulfonamid
clinic
develop
inhibitor
led
fda
approv
amprenavir
treatment
hivaid
develop
carbamatederiv
novel
proteas
inhibitor
shown
figur
design
varieti
inhibitor
incorpor
cyclic
sulfon
bicycl
ligand
figur
compound
ligand
conceiv
order
maxim
hydrogenbond
interact
proteas
backbon
well
fill
hydrophob
pocket
subsit
basi
xray
structur
saquinavirbound
proteas
design
fuse
bicycl
tetrahydrofuran
bisthf
ligand
form
hydrogen
bond
backbon
aspart
subsit
well
fill
hydrophob
site
adjac
ring
saquinavir
figur
xray
structur
analysi
proteas
reveal
bisthf
carbam
mimic
major
bond
saquinavir
detail
studi
also
establish
stereochemistri
bisthf
ring
posit
ring
oxygen
critic
potenc
develop
bisthf
carbam
could
form
network
hydrogen
bond
subsit
proteas
investig
transit
state
isoster
function
form
hydrogen
bond
subsit
basic
hypothesi
design
inhibitor
form
network
hydrogen
bond
proteas
backbon
atom
throughout
activ
site
proteas
subsit
backbon
bind
strategi
combat
drug
resist
led
develop
seri
potent
carbamatederiv
proteas
shown
figur
incorpor
bisthf
ligand
r
hydroxyethylsulfonamid
isoster
bear
pmethoxysulfonamid
ligand
methoxi
oxygen
interact
aspart
backbon
atom
subsit
result
inhibitor
exhibit
notabl
inhibitor
bisthf
ligand
significantli
potent
antivir
assay
correspond
inhibitor
enantiomer
bisthf
ligand
xray
structur
proteas
reveal
carbam
nh
form
hydrogen
bond
backbon
carbonyl
group
carbam
carbonyl
involv
interest
tetracoordin
hydrogenbond
interact
structur
water
molecul
inhibitor
sulfonamid
oxygen
flap
ile
nh
residu
also
structur
reveal
interact
backbon
atom
replac
pmethoxi
group
pamino
group
led
inhibitor
figur
inhibitor
show
mark
enzym
inhibitori
activ
well
antivir
activ
indepth
antivir
studi
reveal
maintain
excel
antivir
activ
multidrugresist
xray
structur
studi
darunavirbound
proteas
show
extens
activ
site
interact
figur
particularli
form
network
hydrogen
bond
protein
backbon
throughout
activ
site
darunavir
also
exhibit
favor
pharmacokinet
properti
subsequ
clinic
develop
led
fda
approv
darunavir
treatment
hivaid
carbam
function
darunavir
assembl
shown
scheme
furan
bisthf
treat
disuccinimidyl
carbon
provid
activ
mix
carbon
reaction
activ
carbon
hydroxyethylsulfonamid
isoster
provid
backbon
bind
inhibitor
design
strategi
combat
drug
resist
util
us
other
advanc
number
preclin
clinic
inhibitor
figur
show
select
bisthfderiv
carbam
mark
enzym
antivir
like
darunavir
inhibitorbound
xray
structur
inhibitor
show
network
hydrogen
bond
subsit
proteas
inhibitor
side
chain
well
bisthf
bicycl
framework
also
effect
fill
hydrophob
pocket
activ
site
outlin
select
number
cyclic
etherderiv
carbam
develop
base
backbon
bind
concept
figur
particularli
incorpor
stereochem
defin
oxacycl
ligand
cpthf
tpthf
tristhf
fluorobisthf
provid
except
potent
inhibitor
clinic
import
carbam
function
inhibitor
particularli
worthi
note
xray
crystal
structur
inhibitor
complex
proteas
provid
ligandbind
site
interact
respons
respect
antivir
potenc
wildtyp
multidrugresist
virus
gener
inhibitor
involv
hydrogenbond
interact
proteas
activ
site
furthermor
ring
cycl
adequ
fill
hydrophob
pocket
activ
follow
discoveri
firstgener
inhibitor
design
synthes
ghosh
tang
shown
figur
util
carbam
deriv
isoster
potent
pseudopeptid
inhibitor
identifi
xray
crystal
structur
determin
provid
molecular
insight
ligand
bind
site
indepth
structur
analysi
thu
provid
critic
drug
design
templat
led
begin
structurebas
design
approach
peptidomimeticnonpeptid
xray
structur
reveal
asparagin
side
chain
carboxamid
nitrogen
form
intermolecular
hydrogen
bond
glutam
acid
carbonyl
group
basi
molecular
insight
number
cycloamidecarbamatebas
macrocycl
inhibitor
design
shown
figur
acycl
carbam
deriv
less
potent
correspond
cyclic
inhibitor
inhibitor
macrocycl
contain
transolefin
amid
carbam
function
within
macrocycl
show
good
inhibitori
activ
satur
inhibitor
less
potent
show
enhanc
potenc
xray
structur
studi
inhibitor
secretas
reveal
carbam
carbonyl
form
hydrogen
bond
side
chain
carboxamid
residu
interestingli
unsatur
inhibitor
show
slight
select
memapsin
ki
nm
design
select
inhibitor
import
reduc
toxic
offtarget
effect
particularli
select
aspart
proteas
pepsin
renin
cathepsin
catd
cathepsin
e
may
import
reduct
side
effect
drug
basi
detail
studi
xray
structur
analysi
design
varieti
highli
select
potent
inhibitor
perspect
highlight
develop
inhibitor
bear
carbam
function
shown
figur
inhibitor
potent
inhibitor
howev
show
select
catd
subsequ
structurebas
design
led
develop
select
inhibitor
contain
pyrazolylmethyl
oxazolymethyl
carbam
posit
inhibitor
show
excel
potenc
select
cathepsin
xray
crystal
structur
reveal
carbam
carbonyl
form
hydrogen
bond
backbon
nh
also
pyrazol
nitrogen
form
strong
hydrogen
bond
side
chain
hydroxyl
group
function
form
number
hydrogen
bond
subsit
well
basi
molecular
insight
oxazolederiv
design
provid
stabl
select
inhibitor
synthesi
inhibitor
outlin
scheme
urethan
prepar
treatment
triphosgen
presenc
triethylamin
follow
lmethionin
methyl
ester
hydrochlorid
saponif
result
methyl
ester
provid
correspond
acid
coupl
amin
acid
describ
previous
subsequ
oxid
sulfid
mchloroperbenzo
acid
furnish
inhibitor
fresko
cowork
report
seri
inhibitor
incorpor
polar
carbam
deriv
strategi
led
improv
catd
select
hypothes
subsit
catd
lipophil
less
toler
polar
group
seen
figur
benzyl
carbam
deriv
display
select
catd
howev
polar
deriv
improv
select
nearli
correspond
methyl
compound
provid
reduct
select
tetrahydrofuranyl
carbam
show
nearli
select
catd
inhibitor
also
shown
good
excel
valu
hek
cell
year
mani
structur
class
potent
select
inhibitor
report
number
inhibitor
display
druglik
properti
also
inhibit
product
anim
model
section
review
inhibitor
carbam
function
basi
inhibitor
peter
cowork
design
seri
carbam
deriv
dibenzazepinon
potent
metabol
stabl
shown
figur
carbam
deriv
prepar
base
subsequ
carbam
emerg
potent
inhibitor
research
pharmacopeia
scheringplough
research
institut
develop
seri
potent
inhibitor
contain
tetrahydroquinolin
sulfonamid
piperidin
sulfonamid
shown
figur
number
repres
carbam
deriv
show
valu
low
nanomolar
rang
racem
carbam
first
show
good
valu
enantiom
separ
hplc
one
enantiom
show
valu
nm
wherea
enantiom
display
nm
absolut
stereochemistri
activ
enantiom
determin
piperidin
carbam
also
show
good
potenc
carbam
deriv
display
good
membran
valu
howev
show
poor
cyp
properti
modif
led
compound
good
inhibitori
activ
improv
cyp
properti
bergstrom
cowork
report
seri
carbamateappend
nalkyl
sulfonamid
figur
depict
select
exampl
show
potent
inhibitori
activ
sulfonamid
deriv
identifi
potent
inhibitor
explor
carbamateappend
nalkylsulfonamid
result
potent
inhibitor
tertiari
carbam
show
signific
reduct
brain
transgen
mice
compar
benzyl
deriv
compound
also
show
improv
braintoplasma
ratio
good
absolut
brain
concentr
serin
proteas
larg
famili
proteolyt
enzym
play
varieti
critic
role
mani
physiolog
deregul
serin
proteas
relat
pathogenesi
diseas
stroke
inflamm
alzheim
diseas
cancer
arthriti
therefor
signific
research
effort
focus
discoveri
serin
proteas
inhibitor
activ
site
serin
proteas
consist
catalyt
triad
ser
asp
nucleophil
attack
hydroxyl
group
serin
carbonyl
carbon
scissil
bond
substrat
via
gener
base
catalysi
histidin
lead
tetrahedr
transit
state
tetrahedr
intermedi
ultim
collaps
lead
cleavag
key
activ
residu
conserv
serin
proteas
xray
structur
studi
reveal
residu
superimpos
major
serin
therefor
select
serin
proteas
repres
key
issu
taken
consider
inhibitor
design
earli
inhibitor
act
via
coval
mechan
electrophil
group
form
coval
bond
serin
hydroxyl
catalyt
triad
electrophil
group
commonli
refer
serin
trap
warhead
howev
coval
inhibitor
lack
select
specif
proteas
class
clan
ration
design
coval
serin
proteas
inhibitor
usual
involv
select
good
substrat
link
serin
trapwarhead
chloromethyl
keton
diphenyl
phosphon
ester
trifluoromethyl
keton
peptidyl
boron
acid
deriv
usual
employ
warhead
basi
warhead
varieti
irrevers
revers
coval
serin
proteas
inhibitor
section
repres
serin
proteas
inhibitor
contain
carbam
function
outlin
carbam
deriv
figur
diphenyl
phosphon
ester
contain
cbz
group
bear
singl
amino
acid
side
chain
show
good
inhibitori
activ
human
plasma
kallikrein
use
treatment
hereditari
thrombin
attract
therapeut
target
drug
develop
pulmonari
embol
thrombosi
relat
compound
show
good
potenc
select
human
thrombin
stabl
display
activ
acetylcholinesteras
select
cystein
proteas
peptidyl
boron
acidbas
thrombin
inhibitor
develop
dupontmerck
particular
nboc
deriv
inhibitor
potent
inhibitor
ki
nm
imperiali
cowork
introduc
trifluoromethyl
keton
specif
serin
proteas
inhibitor
particularli
chymotrypsin
research
astrazeneca
design
numer
peptidyl
trifluoromethyl
keton
deriv
potent
human
elastas
optim
featur
result
develop
number
oral
activ
inhibitor
particular
methyl
carbam
deriv
inhibitor
shown
potent
inhibitor
ki
nm
excel
oral
bioavail
laboratori
optic
pure
compound
configur
isopropyl
side
chain
becam
candid
clinic
develop
potenti
treatment
elastaseimpl
respiratori
diseas
peptidomimet
boron
acidbas
hepat
c
viru
hcv
proteas
inhibitor
design
synthes
treatment
chronic
hcv
infect
hcv
infect
lead
progress
liver
damag
cirrhosi
liver
serin
proteas
play
critic
role
viru
replic
becom
antivir
drug
develop
first
specif
potent
hcv
proteas
inhibitor
good
oral
bioavail
ciluprevir
contain
carbam
function
biln
figur
noncoval
macrocycl
peptid
inhibitor
result
substratebas
approach
design
activ
site
inhibitor
inhibitor
activ
enzymat
nm
cellbas
replicon
assay
nm
hcv
genotyp
ciluprevir
later
discontinu
due
cardiac
toxic
anim
model
develop
pave
way
boceprevir
victr
scheringplough
approv
fda
may
telaprevir
vertex
pharmaceut
johnson
johnson
particular
develop
boceprevir
introduct
ketoamid
moieti
togeth
optim
led
inhibitor
show
ki
xray
crystal
structur
complex
enzym
also
provid
insight
optim
inde
cyclopropylalanin
residu
found
optim
result
carbam
deriv
show
ki
nm
although
inhibitor
display
good
enzym
inhibitori
potenc
display
cellular
activ
subgenom
hcv
replicon
assay
possibl
strong
peptid
discoveri
nmethyl
leucin
critic
enzymat
potenc
cellular
activ
led
potenti
cyclopropylfus
prolin
envisag
optimum
conform
constrain
surrog
part
inhibitor
combin
ligand
previous
optim
residu
provid
carbam
deriv
ki
nm
final
truncat
optim
employ
cyclobutyl
moieti
led
compound
ki
nm
direct
boceprevir
subsequ
compound
figur
carbam
contain
prolin
core
show
potent
inhibitori
activ
nm
nm
similarli
macrocycl
inhibitor
cyclic
boron
show
good
potenc
nm
electronwithdraw
effect
ester
amid
function
also
util
design
transit
state
rang
hcv
proteas
inhibitor
design
synthes
incorpor
templat
scissil
site
structurebas
design
led
varieti
potent
acycl
cyclic
inhibitor
ketoamid
templat
exemplifi
compound
nm
nm
figur
edward
et
al
develop
peptidyl
new
templat
inactiv
elastas
tripeptidyl
inhibit
human
neutrophil
elastas
hne
nm
ketooxazolinederiv
inhibitor
display
potent
activ
hne
nm
carbam
deriv
also
play
key
role
inhibitor
hcv
repres
new
promis
target
hcv
therapi
hcv
zincbind
phosphoprotein
role
hcv
viru
life
cycl
still
howev
play
critic
role
hcv
rna
replic
also
involv
virion
due
lack
enzymat
function
inhibitor
viralencod
protein
research
bristolmy
squibb
screen
librari
compound
abil
inhibit
hcv
rna
replic
led
identif
lead
compound
specif
interf
rna
replic
later
prove
inhibit
activ
protein
subsequ
optim
focus
broaden
genotyp
specif
improv
pharmacokinet
properti
compound
symmetri
molecul
play
import
role
inhibitori
potenc
final
led
discoveri
daclatasvir
figur
firstinclass
inhibitor
hcv
replic
daclatasvir
approv
europ
august
ledipasvir
gilead
scienc
figur
anoth
carbamatecontain
hcv
inhibitor
potent
antivir
activ
hcv
genotyp
harvoni
combin
ledipasvir
sofosbuvir
nucleotid
polymeras
inhibitor
approv
fda
octob
treatment
chronic
hcv
genotyp
infect
also
repres
first
approv
regimen
requir
administr
interferon
cystein
proteas
also
known
thiol
proteas
proteolyt
enzym
respons
degrad
enzym
divid
three
class
base
sequenc
homolog
papain
caspas
picornavirida
famili
papain
famili
proteas
known
cystein
proteas
identifi
varieti
divers
organ
bacteria
eukaryot
microorgan
plant
anim
divid
clan
ca
cd
ce
cf
ch
merop
peptidas
databas
largest
subfamili
among
class
cystein
proteas
papainlik
cystein
proteas
origin
papain
archetyp
cystein
proteas
clan
ca
proteas
util
catalyt
cy
asn
residu
invari
order
primari
sequenc
proteas
clan
ca
famili
papainfamili
cystein
proteas
wellcharacter
mani
eukaryot
organ
also
best
character
plasmodium
cystein
proteas
name
falcipain
belong
papainfamili
clan
ca
enzym
clan
cd
present
two
catalyt
residu
cy
sequenc
clan
ce
triad
form
glu
asp
cy
cterminu
clan
cf
asparagin
residu
catalyt
triad
replac
glutam
residu
catalyt
triad
order
glu
cy
clan
cg
dyad
two
cystein
residu
clan
ch
present
cy
thr
triad
catalyt
cystein
nterminu
proteolyt
mechan
involv
format
ion
pair
provid
highli
nucleophil
cystein
thiol
year
mani
cystein
proteas
inhibitor
design
appropri
link
electrophil
warhead
specif
recognit
sequenc
peptid
substrat
revers
inhibitor
warhead
includ
aldehyd
inhibitor
interact
proteas
activ
site
form
tetrahedr
intermedi
eventu
hydrolyz
regener
enzym
inhibitor
equilibrium
reaction
irrevers
inhibitor
cystein
proteas
includ
epoxid
aziridin
haloketon
vinyl
sulfon
acyloxymethylketon
inhibitor
inactiv
target
alkyl
activ
site
cystein
thiol
perman
disabl
enzym
occurr
sever
acut
respiratori
syndrom
sar
subsequ
identif
novel
coronaviru
etiolog
agent
recogn
cystein
proteas
sarscov
sarscov
plpro
papainlik
proteas
possibl
target
drug
subsequ
structurebas
design
base
previou
inhibitor
xray
cocryst
structur
provid
carbam
deriv
figur
potent
sarscov
inhibitor
wide
varieti
human
rhinoviru
hrv
proteas
inhibitor
develop
incorpor
carbonyl
moieti
warhead
hanzlik
et
al
report
first
hrv
proteas
inhibitor
contain
peptid
portion
incorpor
peptid
part
select
base
substrat
cleavag
site
repres
carbamatecontain
inhibitor
figur
show
valu
nm
human
cathepsin
k
play
critic
role
bone
resorpt
effort
block
bone
resorpt
noncoval
cathepsin
k
inhibitor
develop
kim
et
al
provid
carbam
deriv
figur
noncoval
revers
cathepsin
k
l
inhibitor
glaxowellcom
scientist
develop
carbamatecontain
ketoamidebas
cathepsin
k
inhibitor
figur
nm
start
potent
ketonebas
inhibitor
unsatisfactori
druglik
incorpor
element
ketoamidebas
inhibitor
led
hybrid
seri
ketonebas
cathepsin
k
inhibitor
improv
bioavail
exemplifi
inhibitor
figur
nm
cathepsin
suggest
develop
agent
rang
immun
disord
new
class
nonpeptid
noncoval
cathepsin
inhibitor
report
subsequ
structur
optim
result
potent
competit
noncoval
carbamatecontain
inhibitor
figur
nm
carbam
employ
design
serin
hydrolas
inhibitior
section
focu
inhibitor
endocannabinoid
metabol
enzym
carbam
function
play
import
role
endocannabinoid
system
known
ubiquit
neuromodulatori
system
wide
rang
action
found
everi
primit
organ
compos
cannabinoid
receptor
cbr
endogen
cannabinoid
endocannabinoid
ec
enzym
respons
product
transport
ec
class
signal
lipid
narachidonoyl
ethanolamin
anandamid
aea
oleamid
glycerol
exert
biolog
action
interact
two
gprotein
coupl
receptor
modul
rang
respons
process
includ
pain
inflamm
appetit
motil
sleep
thermoregul
cognit
emot
action
signal
lipid
rapidli
termin
cellular
reuptak
subsequ
hydrolysi
oper
number
enzym
attract
approach
involv
modul
ec
system
aim
elicit
desir
effect
cbr
activ
pharmacolog
inactiv
main
endocannabinoid
metabol
enzym
name
monoacylglycerol
lipas
magl
domain
contain
three
serin
hydrolas
account
approxim
hydrolysi
wherea
fatti
acid
amid
hydrolas
faah
respons
aea
inactiv
enzym
would
elev
endogen
concentr
substrat
consequ
prolong
potenti
benefici
effect
pain
anxieti
without
evok
classic
agonist
side
effect
hypomotil
hypothermia
catalepsi
monoacylglycerol
lipas
magl
primari
enzym
respons
hydrolysi
total
hydrolysi
brain
ascrib
magl
magl
kda
membran
enzym
belong
superfamili
serin
hydrolas
catalyt
triad
repres
ubiquit
present
brain
cortex
hippocampu
cerebellum
thalamu
striatum
local
presynapt
termin
even
lower
level
found
brainstem
hypothalamu
concomit
distribut
membran
well
cytosol
report
magl
share
common
fold
motif
call
fold
studi
recent
year
shown
magl
inhibitor
elicit
antinocicept
anxiolyt
antiemet
respons
magl
inhibitor
also
shown
exert
antiinflammatori
action
brain
protect
neurodegener
lower
eicosanoid
recent
potenti
magl
inhibitor
therapi
fragil
x
syndrom
earli
discov
magl
inhibitor
molecul
abl
target
cystein
residu
present
activ
site
enzym
later
research
focus
synthesi
compound
coval
bind
catalyt
triad
among
carbam
figur
first
select
inhibitor
degrad
although
potenc
remain
limit
rat
brain
select
magl
inhibitor
bear
carbam
scaffold
develop
cravatt
inhibitor
figur
exhibit
select
toward
faah
vitro
nm
human
recombin
magl
faah
respect
recent
cravatt
cowork
report
distinct
class
ohexafluoroisopropyl
hfip
carbam
bear
reactiv
group
bioisoster
endocannabinoid
repres
compound
figur
nm
human
magl
display
excel
potenc
vivo
comparison
previous
describ
oaryl
carbam
inhibitor
show
enhanc
select
faah
serin
gene
encod
kda
protein
contain
ntermin
transmembran
region
follow
catalyt
domain
includ
canon
gxsxg
activesit
motif
serin
hydrolas
uniqu
highli
conserv
enzym
mammal
mainli
express
brain
liver
kidney
brown
adipos
tissu
member
serin
hydrolas
class
predict
hydrolyz
ester
amid
thioester
bond
substrat
could
includ
small
molecul
lipid
peptid
although
full
rang
substrat
regul
enzym
vivo
current
recent
studi
also
shown
carbam
inhibitor
produc
antiinflammatori
neuroprotect
effect
mous
model
traumat
brain
among
optim
inhibitor
figur
display
valu
nm
notabl
faah
membranebound
enzym
belong
amidas
famili
analysi
crystal
structur
reveal
core
compos
characterist
serserli
catalyt
catalyt
residu
faah
buri
deep
within
enzym
access
two
narrow
channel
import
faah
demonstr
gener
faah
knockout
mice
mice
show
elev
rest
brain
concentr
aea
manifest
analges
phenotyp
carrageenan
model
inflammatori
pain
formalin
model
spontan
ii
reduct
inflammatori
iii
improv
slow
wave
sleep
memori
urb
class
compound
first
class
inhibitor
identifi
faah
wellrepres
figur
nm
n
hexylcarbam
analogu
figur
nm
anoth
potent
compound
repres
biphenyl
seri
gattinoni
cowork
develop
seri
oxim
carbam
inhibitor
compound
figur
nm
display
good
affin
select
toward
recent
butini
et
al
develop
new
class
potent
select
faah
revers
carbam
among
compound
figur
ki
nm
mous
brain
faah
show
excel
activ
compound
show
impress
select
toward
enzym
receptor
endocannabinoid
perspect
role
carbam
drug
design
medicin
chemistri
highlight
particular
perspect
cover
physic
properti
carbam
develop
novel
chemic
methodolog
overcom
histor
safeti
toxic
issu
relat
prepar
furthermor
import
carbamatederiv
compound
medicin
chemistri
widespread
employ
drug
prodrug
discuss
also
showcas
exploit
organ
carbam
develop
numer
aspart
acid
serin
cystein
proteas
inhibitor
hope
perspect
stimul
use
organ
carbam
structur
motif
drug
design
medicin
chemistri
